Physician profile
Bryan M Brooks
NPI 1972530673
$5,566.92
in general payments reported to CMS, 2019-2025
23 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,764 · 2020: $535 · 2021: $834 · 2022: $718 · 2023: $389 · 2024: $198 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,947.91 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Notal Vision, INC. | $446.23 | 2019-2025 | Foresee Home |
| Sun Pharmaceutical Industries INC. | $339.86 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.02 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $229.64 | 2020-2022 | |
| Ocular Therapeutix, INC. | $150.02 | 2020 | |
| New World Medical,INC. | $149.81 | 2022 | |
| Bausch & Lomb Americas INC. | $117.04 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $113.45 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $104.31 | 2019-2023 | |
| Allergan, INC. | $90.84 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $90.63 | 2020-2023 | |
| Mallinckrodt Enterprises LLC | $69.99 | 2019 | |
| Alcon Vision LLC | $66.89 | 2019-2024 | Rocklatan |
| Harrow Eye, LLC | $60.75 | 2024-2025 | Iheezo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $57.19 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $50.78 | 2019-2021 | |
| Omeros Corporation | $50.02 | 2019-2021 | |
| Abbvie INC. | $44.37 | 2022 | |
| Sight Sciences, INC. | $41.84 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $35.79 | 2021 | |
| Horizon Therapeutics Plc | $24.24 | 2023 | Tepezza |
| Eyepoint US, INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.